Shambavi Richard, MD

Articles by Shambavi Richard, MD

Shambavi Richard, MDMyeloma | July 17, 2023
In June 2023, a patient death led to the US Food and Drug Administration pausing the iMMagine-1 study.
View More
Saad Z. Usmani, MD, MBA, FACPVideo Insights | June 26, 2023
The panelists highlight key data presented at ASCO 2023.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | June 26, 2023
Toxicities such as cytokine release syndrome as they relate to BCMA bispecific antibodies for myeloma are discussed.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | June 26, 2023
The panel discusses the new and emerging bispecific antibody treatment options for multiple myeloma.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | June 26, 2023
The panel discusses data on the BCMA CAR-T construct PHE885 and the manufacturing needs that persist.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | June 26, 2023
The panel discusses the real-world data and first-hand experience with the two FDA-approved CAR T-cell therapies for MM.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | June 23, 2023
The panelists discuss their experience with CAR-T access challenges in the real-world clinical setting.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | June 23, 2023
The panel discusses the FDA-approved BCMA-directed CAR-T options for multiple myeloma.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | June 22, 2023
The panel discusses maintenance therapy options for early-relapsed multiple myeloma.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | June 9, 2023
The panel considers triplet versus quadruplet therapy for myeloma induction.
Thomas Martin, MDVideo Insights | May 2, 2023
The panel advises on patient hand off to local care teams following CAR T-cell therapy for myeloma.
Thomas Martin, MDVideo Insights | May 2, 2023
The panel discusses side effect management with CAR T-cell therapy.
Thomas Martin, MDVideo Insights | May 1, 2023
The panel addresses the choice between treating multiple myeloma with a bispecific agent or CAR T-cell therapy.
Thomas Martin, MDVideo Insights | May 1, 2023
Drs. Martin and Voorhees discuss patient characteristics and populations that are suited for CAR-T therapy in myeloma.
Thomas Martin, MDVideo Insights | April 28, 2023
The panel addresses the potential for frontline CAR-T use.
Thomas Martin, MDVideo Insights | April 28, 2023
The panel debates whether CAR-T can be moved earlier in the course of myeloma treatment.
Thomas Martin, MDVideo Insights | April 27, 2023
The panel discusses allogeneic CAR T-cell therapy and how it stacks up against autologous options.
Thomas Martin, MDVideo Insights | April 27, 2023
Drs. Lonial and Martin discuss allogeneic, off-the-shelf CAR-T data.
Thomas Martin, MDVideo Insights | April 26, 2023
BCMA-targeted autologous CAR T-cell therapies are discussed.
Thomas Martin, MDVideo Insights | April 26, 2023
The panel discusses the second FDA-approved CAR-T therapy for myeloma, ciltacabtagene autoleucel.